Day: May 8, 2023

Conference Call Today at 10 a.m. ET PARSIPPANY, N.J., May 08, 2023 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (Nasdaq: LINC) today announced operating and financial results for the first quarter as well as recent business developments. First Quarter 2023 Financial Highlights and Recent Operating Developments*Revenues of $86.4 million grew 6.9% New student starts increased 6.4% Adjusted EBITDA of $2.2 million Increasing outlook for revenues and earnings for the full year*Note: The highlighted financial results exclude the Transitional segment and results and guidance in this release, including the highlights above, include references to non-GAAP operating measures. A reconciliation of GAAP / non-GAAP measures is included in this release. “Our efforts to build more scalable and higher return operations that benefit...

— Completed enrollment in BROOKLYN Phase 3 clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia (“HeFH”) ahead of schedule; topline results expected in 2H 2024 — — Announced positive topline results in January 2023 and scheduled to present full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and ezetimibe at the National Lipid Association (“NLA”) Scientific Sessions in June 2023 — — Expect to report topline results from Phase 2 dose-finding trial of obicetrapib in Japanese patients with dyslipidemia and from Phase 2a trial evaluating obicetrapib in patients with early Alzheimer’s disease in 2H 2023 — — Topline data from pivotal Phase 3 BROADWAY and PREVAIL trials on-track to be announced in 2H 2024 and 2026, respectively...

Represents First Ever Natural Killer Immunotherapy trial in Metastatic Castration-Resistant Prostate Cancer Webinar at 11AM ET on Friday, May 12.BOCA RATON, Fla., May 08, 2023 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for INKmune™, a novel natural killer (NK) cell immunotherapy, for a Phase I/II open-label clinical trial for the treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC).  The Company believes this is the first NK immunotherapy trial in men with mCRPC, which affects more than 80,000 men in the U.S.  The trial is expected to enroll the first of 30 patients in the second half of 2023. It will be opened at 4 more clinical study sites, with a goal to determine short and...

PDUFA date of May 19, 2023 Presented clinical data at ARVO on topical application of B-VEC to the eye to treat ocular complications in a patient with recessive dystrophic epidermolysis bullosa under Compassionate Use Program Strong balance sheet, closing the quarter with $355.5 million in cash, cash equivalents and investments PITTSBURGH, May 08, 2023 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today reported financial results and key operational progress updates for the first quarter ended March 31, 2023. “Krystal had a strong start to 2023, marked by significant progress in commercial preparation activities for our anticipated FDA approval of B-VEC later this month, as well as advancements...

Recursion’s Pipeline Recursion’s internal pipeline as of Q1 2023Entered into agreements to acquire Cyclica and Valence to bolster digital chemistry and generative AI capabilities in order to further create new chemical composition of matter for novel biological targets Advanced 4 active clinical trials, including an exploratory Phase 2 study of REC-994 in Cerebral Cavernous Malformation where more than 80% of planned participants have enrolled Phase 2 trial in AXIN1 or APC mutant solid tumors remains on track to initiate in early 2024 Advanced our RBM39 HR-proficient ovarian cancer program (previously identified as Target Gamma) to the preclinical stage and have initiated IND-enabling studiesSALT LAKE CITY, May 08, 2023 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space...